Sionna Therapeutics Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
59
- Stock Symbol
-
SION
- Investments
-
1
- Share Price
-
$2.97
- (As of Thursday Closing)
Sionna Therapeutics General Information
Description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Contact Information
Website
www.sionnatx.comCorporate Office
- 21 Hickory Drive
- Suite 500
- Waltham, MA 02451
- United States
Corporate Office
- 21 Hickory Drive
- Suite 500
- Waltham, MA 02451
- United States
Sionna Therapeutics Stock Performance
As of 19-Nov-2026, Sionna Therapeutics’s stock price is $2.97. Its current market cap is $134M with 45.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.97 | $2.96 | $2.89 - $54.97 | $134M | 45.2M | 1.15M | -$2.44 |
Sionna Therapeutics Financials Summary
As of 30-Sep-2026, Sionna Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 34,855 | 1,596,667 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (119,894) | (87,916) | (69,190) | (49,449) |
| Net Income | (109,523) | (75,268) | (61,688) | (47,263) |
| Total Assets | 263,261 | 325,953 | 185,752 | 51,945 |
| Total Debt | 7,751 | 8,677 | 9,749 | 10,477 |
Sionna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sionna Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sionna Therapeutics Comparisons
Industry
Financing
Details
Sionna Therapeutics Competitors (1)
One of Sionna Therapeutics’s competitors is Stablix, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Stablix | Venture Capital-Backed | Boston, MA |
Sionna Therapeutics Patents
Sionna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128667-A1 | Nbd1 modulators and methods of using the same | Pending | 11-Dec-2024 | ||
| AU-2025232488-A1 | Methods of treating cftr-mediated diseases or disorders | Pending | 06-Mar-2024 | ||
| WO-2025189008-A1 | Methods of treating cftr-mediated diseases or disorders | Pending | 06-Mar-2024 | ||
| WO-2025189008-A8 | Methods of treating cftr-mediated diseases or disorders | Pending | 06-Mar-2024 | ||
| AU-2024397852-A1 | Compounds, compositions, and methods of using thereof | Pending | 15-Dec-2023 | C07D513/18 |
Sionna Therapeutics Signals
Sionna Therapeutics Investments (1)
Sionna Therapeutics’s most recent deal was a Corporate Asset Purchase with AbbVie (Rights of Cystic Fibrosis Therapies). The deal was made on 16-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AbbVie (Rights of Cystic Fibrosis Therapies) | 16-Jul-2024 | Corporate Asset Purchase | Buildings and Property |
Sionna Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Sionna Therapeutics FAQs
-
When was Sionna Therapeutics founded?
Sionna Therapeutics was founded in 2019.
-
Where is Sionna Therapeutics headquartered?
Sionna Therapeutics is headquartered in Waltham, MA.
-
What is the size of Sionna Therapeutics?
Sionna Therapeutics has 59 total employees.
-
What industry is Sionna Therapeutics in?
Sionna Therapeutics’s primary industry is Drug Discovery.
-
Is Sionna Therapeutics a private or public company?
Sionna Therapeutics is a Public company.
-
What is Sionna Therapeutics’s stock symbol?
The ticker symbol for Sionna Therapeutics is SION.
-
What is the current stock price of Sionna Therapeutics?
As of 19-Nov-2026 the stock price of Sionna Therapeutics is $2.97.
-
What is the current market cap of Sionna Therapeutics?
The current market capitalization of Sionna Therapeutics is $134M.
-
Who are Sionna Therapeutics’s competitors?
Stablix is a competitor of Sionna Therapeutics.
-
What is Sionna Therapeutics’s annual earnings per share (EPS)?
Sionna Therapeutics’s EPS for 12 months was -$2.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process